Liso-cel achieved a 95.5% overall response rate and a 62.1% complete response rate in MZL patients after at least two prior therapies. The two-year overall survival rate for patients treated with liso ...

DelveInsight’s “Marginal Zone Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It ...

A Prescription Drug User Fee Act target date of December 5, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

The National Institute for Health and Care Excellence (NICE) has approved the use of zanubrutinib (Brukinsa, BeiGene) on the NHS in England for the treatment of marginal zone lymphoma (MZL).

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial. Velcade (bortezomib), Rituxan ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Hsi: It's been a ...

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from the ongoing phase 2 MorningSun trial of subcutaneous ...

HOUSTON -- Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, ...